Address: 1787 Sentry Parkway West Building 18, Suite 400 Blue Bell, PA 19422-2200
Tel: 82 267.440.4200
VGX™ Pharmaceuticals is a leading biopharmaceutical company with strong product candidates for the treatment of infectious diseases, including HIV, as well as cancer and inflammatory diseases. The Company’s clinical development programs include PENNVAX™-B, a DNA vaccine for the prevention of HIV in Phase I clinical trials; VGX-1027, a small molecule drug for inflammatory diseases in Phase I clinical trials; VGX-3100, a DNA therapetic vaccine for cervical cancer in Phase I clinical trials; and CELLECTRA® delivery device in Phase I clinical trials.In addition, VGX has filed INDs for VGX-3200 and VGX-3400 for cancer cachexia and avian influenza, respectively.The lead therapeutic programs in infectious diseases and oncology are well complemented by a strong research pipeline of next-generation DNA vaccines. VGX’s proprietary content, coupled with a patented DNA delivery system (CELLECTRA® electroporation), and acess to state-of-the-art cGMP plasmid Manufacturing capabilities form the Company’s DNA Vaccines and Therapies Platform, which gives VGX a unique position relative to its peers with DNA vaccines and therapeutics programs.
Could you briefly introduce VGX International to our readers, and in particular explain its relation to US-based company VGX Pharmaceutical (VGXP)? The backbone of VGXP is the University of Pennsylvania…
The Korean Institute of Toxicology (KIT) is a government-funded research institute that evaluates the safety of medicine, bio-related products and chemicals. PharmaBoardroom talks to Lee Sang-Joon, President of KIT about…
Korea possesses enormous potential to become an exporter of futuristic health systems in the near future, and has already started the process. Kim Han-Joong, chairman of the strategy committee at…
The Korea Drug Research Association (KDRA) was founded in 1986 to represent local pharmaceutical companies in their mission for global drug development. Kang-Choo Lee, president of KDRA, discusses the current…
The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country. You became president…
The head researcher at P&K Skin Research Center discusses the potential of South Korea as a clinical trial hub, and the company’s current expansion plans. What differentiates P&K Skin…
Don Hyun, president of MSD Korea, shares his vision to bring Korean pharmaceutical companies to the global stage and to bring a locally produced drug to blockbuster status in the…
The director of the Hanyang University Hospital for Rheumatic Diseases (HUHRD), discusses Korea’s leading role in developing biosimilars as well as the hospital’s efforts to curb chronic diseases. As…
The Korea National Enterprise for Clinical Trials (KoNECT) was established in 2007 by the Korean government to meet the increasing demand for local clinical trials and strengthen the country’s clinical research…
The director general of Korea’s Bureau of Health Industry explains what has led to Korea’s excellent healthcare system, and the competitiveness of the country’s pharmaceutical sector. Can you provide our…
Jung Kee-Taig, president of the Korea Health Industry Development Institute (KHIDI), outlines his “Health Economy 2030” for Korea, and highlights the institute’s domestic and international collaborations. KHIDI aims to…
Prior to founding Bioneer, Park Han-Oh spent a number of years working at KRIBB. Today he speaks about the company’s latest breakthrough technology in DNA synthesis and his outlook for…
Oh Pil-Soo, managing director of Lundbeck Korea, talks about the challenges of pricing and reimbursement in the CNS area and remaining committed to Korea in terms of clinical research. …
See our Cookie Privacy Policy Here
